U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT07466550) titled 'A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult Participants' on March 09.
Brief Summary: The purpose of this study is to compare how the drug moves through the body following risankizumab subcutaneous (SC) and risankizumab intravenous (IV) doses.
Study Start Date: March 08
Study Type: INTERVENTIONAL
Condition:
Healthy Volunteer
Intervention:
DRUG: Risankizumab
Intravenous (IV)
DRUG: Risankizumab
Subcutaneous (SC) Injections
Recruitment Status: NOT_YET_RECRUITING
Sponsor: AbbVie
Published by HT Digital Content Services with permission from Health...